Adult Dosing
Seasonal allergic rhinitis, perennial allergic rhinitis
Omnaris
- 2 sprays/nostril/day, 50 mcg/spray
- Max: 200 mcg/day
Zetonna
- 1 spray/nostril/day, 37 mcg/day
- Max: 74 mcg/day
Pediatric Dosing
- Safety and efficacy in pediatric patients <11 yrs of age for the treatment of the symptoms of perennial allergic rhinitis have not been established
Seasonal allergic rhinitis
Omnaris
- >6 yrs: 2 sprays/nostril/day, 50 mcg/spray
- Max: 200 mcg/day
Zetonna
- Safety and efficacy in pediatric patients <12 yrs of age have not been established
- >12 yrs: 1 spray/nostril/day, 37 mcg/day
- Max: 74 mcg/day
See Supplemental Patient Information
- Epistaxis, nasal septal perforation, nasopharyngeal candida infections may occur. Periodically examine patients for evidence of candida infections and adverse effects on the nasal mucosa. Discontinue use in the event of localized nasopharyngeal infections
- Avoid spraying directly in to the nasal septum
- Has an inhibitory effect on wound healing, prohibit use in patients with unhealed nasal septal ulcer, nasal surgery or trauma
- Corticosteroids cause development of glaucoma and/or cataracts. Monitor patients with history of increased IOP, glaucoma, and/or cataracts for changes in vision
- Increased risk of immunosuppression and infections; avoid exposure of patients who have not suffered from chickenpox/measles or have been properly immunized. Start prophylaxis with varicella zoster immune globulin (VZIG) if exposed to chickenpox and with pooled immunoglobulin (IG) if exposed to measles
- Adrenal insufficiency and hypercorticism may occur at higher than recommended dosages or even at recommended dosages in susceptible individuals. Withdraw gradually to discontinue
- Reduction in growth velocity may occur in pediatric patients; monitor periodically
Cautions: Use cautiously in
- Active or quiescent tuberculosis infections of the respiratory tract
- Untreated local or systemic fungal or bacterial infections
- Systemic viral or parasitic infections
- Ocular herpes simplex infections
- Measles or varicella exposure
- Glaucoma
- Cataracts
- Increased intra ocular pressure
- Adrenal insufficiency
- Adrenal suppression
- Hypercorticism
Supplemental Patient Information
- Avoid spraying directly in to the nasal septum
- Gently shake nasal spray during initial use, primed the pump by actuating eight times
- Gently shake and reprime the pump with one spray or until a fine mist appears if the product is not used for 4 consecutive days
Pregnancy Category:C
Breastfeeding: Safety unknown; amount of corticosteroid absorbed into the blood and excreted in breast milk is too small to adversely affect breastfed infant. Inhaled corticosteroids are acceptable to use during breastfeeding. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 11 November 2010). Manufacturer advises caution
Pricing data from www.DrugStore.com in U.S.A.
- Omnaris 50 MCG/ACT SUSP [Inhaler] (SUNOVION PHARMACEUTICALS)
12.5 act = $119.99
37.5 act = $345.96
Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.
6 years of age
